A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis
Transfusion · 2024
DOI: 10.1111/trf.17865 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transfusion, 2024. Verfasst von Amelework Wodajo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Plasma Exchange, Fibrinogen, Hemorrhage. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Plasma exchange (PLEX) therapy is indicated for several disorders. The 5% albumin is often used as a sole replacement fluid during most PLEX. However, each 1.0 plasma volume exchange depletes coagulation factors by ~65%. Although most coagulation factors recover to hemostatic levels within 24 h post‐PLEX, fibrinogen requires 48–72 h to recover. Fibrinogen is the key coagulation protein for hemostasis. Therefore, fibrinogen is often monitored during the acute course of PLEX, and plasma is supplemented to prevent bleeding if fibrinogen is 100 mg/dL.
Results
Among the 275 patients who received 1406 PLEXes, 62 patients (23%) who underwent 323 PLEXes met the inclusion criteria, and only 2 (3%) patients had bleeding while on oral anticoagulants. In contrast, out of 275 patients, 143 (52%) with fibrinogen levels >100 mg/dL received 751 PLEX treatments, and bleeding occurred in 2 (1%) while on low‐molecular‐weight heparin.
Conclusions
Our findings suggest that a pre‐procedure fibrinogen threshold of 80–100 mg/dL without plasma supplementation does not increase bleeding risk unless patients were on anticoagulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
- Department of Internal Medicine (Hematology/Oncology), Dallas, Texas, USA.
- Carter BloodCare, Bedford, Texas, USA.
- Department of Pathology, University of California San Diego, San Diego, California, USA.
ORCID-Profile: Amelework Wodajo, Christopher Webb, Amena Usmani
Zitieren
APA
Wodajo, A., Sarode, R., Valiyaparambil, S., Webb, C., De Simone, N., Rebecca, D., & Usmani, A. (2024). A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis. Transfusion. https://doi.org/10.1111/trf.17865
Vancouver
Wodajo A, Sarode R, Valiyaparambil S, Webb C, De Simone N, Rebecca D, et al. A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis. Transfusion. 2024. doi:10.1111/trf.17865
BibTeX
@article{Wodajo2024,
author = {Wodajo, Amelework and Sarode, Ravi and Valiyaparambil, Shiney and Webb, Christopher and De Simone, Nicole and Rebecca, Dill and Usmani, Amena},
title = {A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17865}
}
EUVIMED